Press release
Antibody Drug Conjugates Market by Demand Analysis, Manufacturers Share, Regions, Risk Analysis, Driving Forces and Application, Forecast to 2028
Download Sample PDF Copy https://www.theinsightpartners.com/sample/TIPRE00003494
The market growth of antibody drug conjugates is due to the growing strategic partnerships to develop antibody drug conjugates, rising incidences of cancer cases, and increasing FDA approvals for ADCs. Whereas high cost of ADCs development and commercialization is hindering the market growth.
Asia Pacific is the fastest-growing region of the global newborn screening market in 2022. The projected growth of the market in this region can be associated with the growth of the ADCs market is widely driven by company collaborations, growing incidences of cancer, and increasing clinical trials. China is home to various innovators of ADCs that are exponentially contributing to the market growth. Players such as RemeGen Co., Ltd.; Zhejiang Medicine Co., Ltd.; and Jiangsu Hengrui Pharmaceuticals Company Ltd. are among the leaders in the ADCs market in the country. These companies are involved in developing ADCs that can treat breast, gastric, and urothelial cancers.
ADC Therapeutics SA, Pfizer Inc, F. Hoffmann-La Roche Ltd, ImmunoGen, Inc., GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd. are among the leading companies operating in the vital signs monitoring devices market.
Companies operating in the antibody drug conjugates market adopt various organic and inorganic strategies. Growth strategies mainly include product launches and product approvals, mergers & acquisitions, collaborations, and partnerships are among the growth strategies witnessed in the antibody drug conjugates market.
A few of the significant developments by key market players are listed below.
In September 2022, Seagen Inc., pioneer and a world leader in antibody drug conjugate (ADC) therapies, and RemeGen Co., Ltd. have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC. This collaboration leverages Seagen's world-class expertise and knowledge of ADC development, manufacturing and commercialization to maximize the potential of disitamab vedotin.
In September 2022, ImmunoGen, Inc. has entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize ELAHERE (mirvetuximab soravtansine-gynx) in Japan. The collaboration further supports the strategy to bring ELAHERE to eligible patients with folate receptor Alpha (FR?)-Positive, platinum-resistant ovarian cancer globally.
Companies have pipeline products to be launched in the market after completing the clinical trials. In June 2023, RemeGen Co., Ltd. signed an agreement with Innovent Biologics, Inc. to enter clinical trials and supply combination therapies TYVYT (sintilimab injection) with RC88, a novel mesothelin(MSLN)-targeting antibody-drug conjugate (ADC), or TYVYT with RC108, a novel c-Met-targeting ADC. These are claimed to be novel therapies to treat solid tumors. Under the agreement, RemeGen Co., Ltd will conduct Phase 1/2a clinical studies for TYVYT to evaluate the anti-tumor activity and safety. The company also has Distamab vedotin (RC48) +PD1 combination in the pipeline. The combination is evaluated in two phases for different cancer indications, first combination is in phase III, evaluated to treat urothelial cancer in and second is in phase II, evaluated to treat muscle invasive bladder and gastric cancer.
As of April 2023, Zhejiang Medicine Co., Ltd. and Jiangsu Hengrui Pharmaceuticals Company Ltd. have ARX788 + pyrotinib maleate and SHR-A1811 + pyrotinib maleate, respectively, in phase II and are developed to treat breast cancer. Thus, the commercialization of pipeline products in the country would help the market grow exponentially in the coming years.
Enquire before buying at https://www.theinsightpartners.com/buy/TIPRE00003494
The antibody drug conjugates market, by application, is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. In 2022, the breast cancer segment held the largest market share, and is estimated to register the fastest CAGR during 2022-2030. The use of ADCs has significantly transformed how breast cancer treatment is planned. The development of ADCs is expected to improve breast cancer therapeutics' potency, precision, and safety. At present, Kadcyla/T-DM1 (ado-trastuzumab emtansine), Enhertu/T-DXd (trastuzumab deruxtecan), and Trodelvy/SG (sacituzumab govetican) are the commercialized products available in the market to treat triple-negative breast cancer (TNBC) and metastatic breast cancer cases. According to the Breast Cancer Research Foundation data, published in January 2023, 17 ADCs are in clinical trials. 9 out of these are HER2-directed ADCs, which are being studied in different combinations of payloads. The remaining 8 ADCs are being studied in combination with novel antibody targets.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Ankit Mathur
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
About Us:
TIP is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antibody Drug Conjugates Market by Demand Analysis, Manufacturers Share, Regions, Risk Analysis, Driving Forces and Application, Forecast to 2028 here
News-ID: 3239013 • Views: …
More Releases from The insight partners
The Evolution of Solar Energy: Next Generation Solar Cells Lead the Green Revolu …
Next-generation solar cells represent the evolution of photovoltaic technology, offering higher efficiency, lower manufacturing costs, and greater versatility compared to traditional silicon-based solar panels. These advanced solar cells include technologies such as perovskite, organic photovoltaics (OPV), quantum dot, multi-junction, and thin-film cells. They are designed to overcome the limitations of conventional systems.
To Get Sample Copy of Report, Click Here - https://www.theinsightpartners.com/sample/TIPRE00039557/?utm_source=OpenPR&utm_medium=10607
The Global Next Generation Solar Cell market size was…
Large Generator Market Set for Robust Growth Driven by Rising Industrialization …
10 October 2025 - [New York, US] - The global Large Generator Market is poised for substantial expansion over the coming years, fueled by increasing industrialization, rapid infrastructure development, and growing demand for uninterrupted power supply across critical sectors. Large generators, which are capable of producing high-capacity power for heavy-duty applications, are gaining significant traction in industries such as oil & gas, manufacturing, mining, data centers, and utilities.
The large generator…
Global Synthetic Musk Market Set for Robust Expansion through 2031
New York, US - October 10, 2025 - A new publication from The Insight Partners, titled "Synthetic Musk Market Share, Size, Trends, and Forecast by 2031," anticipates significant and steady expansion for the global synthetic musk sector. The report offers critical perspectives on the current market status, expected future growth, primary factors driving its progress, existing challenges, and lucrative opportunities. These insights are intended to inform various corporate stakeholders. The…
WiFi 6 Device Market Explained: Opportunities, Challenges, and What's Next
The transition from WiFi 5 (802.11ac) to WiFi 6 (802.11ax) is reshaping the wireless connectivity landscape. As devices proliferate and users demand ever higher throughputs, lower latency, and better concurrency, WiFi 6 has become the go to standard for new deployments. According to the Wi Fi 6 Devices Market Report from The Insight Partners, the global WiFi 6 device market is projected to grow strongly through 2031.
Check valuable insights…
More Releases for ADC
ADC Market: Transforming Cancer Treatment
The global market for antibody-drug conjugates (ADCs) was valued at US$ 11.32 billion in 2023 and is expected to reach US$ 27.37 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for safe and effective treatments.
Antibody Drug Conjugates: A Growing Force in Cancer Treatment and Market Expansion
Key…
With Knockout ADC Innovations, Creative Biolabs Took Center Stage at the 2024 Wo …
Creative Biolabs wrapped up a successful show at the 15th Annual World ADC San Diego in the beginning of November, where its third year of participation, highlighting its dedication to the advancement of antibody-drug conjugate (ADC) technology.
New York, USA - November 13, 2024 - Creative Biolabs seized the spotlight at Booth 313 by offering groundbreaking solutions across the entire ADC development spectrum, which demonstrate their unrivaled expertise and dedication to…
Showing Off Their ADC Game: Creative Biolabs Hits the 15th Annual World ADC Summ …
From November 4, Creative Biolabs will be back at the 15th Annual World ADC Summit in San Diego, marking its fourth year at the leading global gathering featuring innovative conjugates.
New York, USA - November 6, 2024 - Creative Biolabs invites all ADC enthusiasts, from new entrants to seasoned experts, to explore its comprehensive suite of ADC solutions and experience the latest in antibody-drug conjugate (ADC) innovation at Booth #313.
Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg
"2023…
ADC Drugs For Breast Cancer Treatment
Breast cancer is the malignant tumor with the highest morbidity and mortality among women worldwide. At present, the main therapeutic methods include surgery, chemotherapy, radiotherapy, endocrine therapy and targeted therapy, etc. The development and marketing of new drugs have far-reaching significance in improving the survival of breast cancer patients and changing the pattern of breast cancer treatment.
On February 24, 2023, The NMPA approved Enhertu, an injectable drug developed jointly by…
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Succe …
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Successive Approximation ADC, Delta-sigma ADC, and Others (Pipelined/Flash ADC)), and Application (Consumer Electronics and Industrial) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Full Report : https://www.alliedmarketresearch.com/analog-to-digital-converters-market
Increasing disposable income and technological advancements supplement the analog-to-digital converters market. However, complex design of the ADC hampers this market growth. On the other hand, encouragement in digitization of work processes by government in emerging economies,…
Global Data Converters Market Report 2017 (Analog to Digital Converter, Current …
The research report titled Global Data Converters Sales Market Report 2017 market size and forecast and overview on current market trends.
This report studies sales (consumption) of Global Data Converters Market 2017, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering
National Semiconductor
Nippon Precision Circuits Inc
Micro Analog systems
Microchip Technology.
TelCom Semiconductor, Inc
Vishay Siliconix
Texas…
